Anzeige
Meldung des Tages: Gold im Fokus: Warum diese milliardenschwere Goldaktie vom aktuellen Goldumfeld profitieren könnte

Icecure Medical Aktie News

Aktie
WKN:  A1W1LG ISIN:  IL0011224156 US-Symbol:  ICCM Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  Israel
0,552 $
-0,048 $
-8,00%
0,46829 € 05.02.26
Depot/Watchlist
Marktkapitalisierung *
34,19 Mio. €
Streubesitz
52,20%
KGV
-
Index-Zuordnung
-

Icecure Medical News

15.09.25 - PR Newswire
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
IceCure Receives Regulatory Approval in Israel for its Next-​Generation XSense™ Cryoablation System for Breast Cancer and Other Indications PR Newswire
08.09.25 - PR Newswire
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® ...
04.09.25 - PR Newswire
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy PR Newswire
13.08.25 - PR Newswire
IceCure Reports Financial & Operational Results for the First Half of 2025
IceCure Reports Financial & Operational Results for the First Half of 2025 PR Newswire
06.08.25 - PR Newswire
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025 PR Newswire
29.07.25 - PR Newswire
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
IceCure Announces Expiration and Results of Approximately Two Times Over-​Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million PR Newswire
25.07.25 - PR Newswire
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation PR Newswire
24.07.25 - PR Newswire
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period PR Newswire
10.07.25 - PR Newswire
IceCure Announces Commencement of Rights Offering
IceCure Announces Commencement of Rights Offering PR Newswire
03.07.25 - PR Newswire
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025 PR Newswire
25.06.25 - PR Newswire
IceCure Announces Record Date for Rights Offering for Up to $10 Million
IceCure Announces Record Date for Rights Offering for Up to $10 Million PR Newswire
09.06.25 - PR Newswire
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes PR Newswire
28.05.25 - PR Newswire
IceCure Medical Reports First Quarter 2025 Financial Results
IceCure Medical Reports First Quarter 2025 Financial Results PR Newswire
21.05.25 - PR Newswire
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025 PR Newswire
06.05.25 - PR Newswire
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation PR Newswire
30.04.25 - PR Newswire
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-​Stage Breast ...
28.04.25 - PR Newswire
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium PR Newswire
22.04.25 - PR Newswire
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation PR Newswire
27.03.25 - PR Newswire
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America PR Newswire
24.03.25 - PR Newswire
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-​Free Rate PR ...

Newssuche

Videos

newspaper
05.02.26 +8,33%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »